drugset / Trial / NCT04155515
A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A Phase III, Multicenter, open-labeded study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I Infected Patients
Timeline
- Start
- 2019-06-13
- Primary completion
- 2020-08-11
- Completion
- 2020-08-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Furaprevir | Small molecule | 400 mg | — |
| Subject | Ribavirin | Small molecule | 1000 mg | — |
| Subject | Ribavirin | Small molecule | 1200 mg | — |
| Subject | Yimitasvir | Small molecule | 200 mg | — |